Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19
Our results suggest that active smokers may be protected against symptomatic covid-19. This was true for outpatients (who have less serious infections) as well as for hospitalized patients. Nicotine and the nicotinic receptor (and not the smoke of cigarettes per se, which is responsible for a very heavy public health burden with more than 78,000 deaths per year in France) may be indeed involved in the pathway leading to viral infection, and particularly in the most severe forms of the disease. Nicotine administration, e.g. via a transcutaneous route may be tested as a therapy to recapitulate the protecting effect of smoking against SARS CoV2 infection.
No comments:
Post a Comment